Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer
With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development  Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC’s preclinical
View HTML
Toggle Summary AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting
- Poster presentation highlights safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) - GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting
View HTML
Toggle Summary AGTC Appoints Hope D’Oyley-Gay as General Counsel
Ms. D’Oyley-Gay brings significant legal experience as well as business development and commercial operations expertise from both biotech and pharmaceutical companies GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC),
View HTML
Toggle Summary AGTC to Participate in the Stifel 2021 Virtual Healthcare Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021
-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET - GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation
View HTML
Toggle Summary AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases,
View HTML
Toggle Summary AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC Announces Two Key Leadership Team Appointments
- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Oct. 14, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company
View HTML
Toggle Summary AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration
Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical Trials GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting human clinical trials
View HTML
Visionary science for life changing cures.